BASEL, Switzerland, March 13, 2019 / B3C newswire / -- NBE-Therapeutics AG, a biopharmaceutical company developing next-generation, immune-stimulatory antibody-drug conjugates (iADCs) for improved cancer therapy, today announces that it will present a late-breaking abstract at the Annual Meeting of the American Association for Cancer Research (AACR) to be held from March 29 - April 3, 2019 in Atlanta, Georgia, U.S. (abstract number LB-197). The title of the late-breaking abstract selected by AACR is: "NBE-002, an anthracycline-based immune-stimulatory antibody drug conjugate (iADC) targeting ROR1 for the treatment of triple-negative breast cancer". The abstract discusses the profound in vivo anti-tumor efficacy of NBE's lead iADC program, NBE-002, in preclinical, patient-derived triple-negative breast cancer models over a wide range of ROR1 expression levels, as well as the potent immune-oncology function of NBE's iADC platform. A poster will be presented in the Immunology session at AACR on:
Date: Tuesday April 2, 2019
Time: 8:00am to 12:00pm
Abstract number: LB-197
The NBE team will present the detailed data to industry stakeholders at a workshop from 06:30 to 8:00 p.m. on the same day. Participation in the event is by invitation only.
“This late-breaking abstract shows the continuous innovation at NBE-Therapeutics and is an exciting demonstration of the best-in-class long-lasting anti-tumor efficacy of NBE-Therapeutics' iADC platform in one of oncology`s most challenging fields of triple-negative breast cancer”, said Roger Beerli, NBE`s Chief Scientific Officer.
NBE develops next-generation iADCs based on its proprietary, site-specific SMAC-technology™ and a novel highly potent anthracycline-based toxin platform. NBE has the objective to develop first- and best-in-class ADC product candidates against tumor targets in cancer indications of high unmet medical need. Its first lead candidate NBE-002 is forecasted to enter clinical trials in 2020.
About NBE-Therapeutics AG
NBE-Therapeutics is a privately owned Basel, Switzerland, based Biotech company, founded in 2012 with the vision to develop first- and best-in-class Antibody Drug Conjugates and to advance them to a clinical proof of concept. The company leverages proprietary platforms covering all aspects of ADC development: its patented Transpo-mAb Display™ technology for antibody discovery, its patented SMAC-Technology™ for site-specific payload conjugation with its highly potent anthracycline-based linker-toxin platform. The company is financially backed by Boehringer Ingelheim Venture Fund, PPF Capital Partners Fund, Novo Holdings and additional private investors.
Chief Business Officer,
+41 61 633 2230
Published by B3C newswire and shared through Newronic®